MedPath

SUN XIAODONG

🇪🇸Spain
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:0

Trial Phases

1 Phases

Phase 4:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 4
2 (100.0%)

Efficacy and Safety of Two Regimens of Anti-VEGF Therapy in Chinese Patients With Polypoidal Choroidal Vasculopathy

Phase 4
Conditions
Polypoidal Choroidal Vasculopathy
Interventions
Procedure: OCTA plus OCT guided 3+PRN regimen
Procedure: OCT guided 3+PRN regimen
Drug: Anti-VEGF drug
First Posted Date
2020-05-08
Last Posted Date
2020-05-08
Lead Sponsor
Xiaodong Sun
Target Recruit Count
102
Registration Number
NCT04380974
Locations
🇨🇳

Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China

Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration

Phase 4
Conditions
Age-related Macular Degeneration
Interventions
Procedure: Treat-and-Extend regimen
Procedure: Pro Re Nata
First Posted Date
2016-06-16
Last Posted Date
2020-05-19
Lead Sponsor
Xiaodong Sun
Target Recruit Count
141
Registration Number
NCT02802657
Locations
🇨🇳

Central Theater Command General Hospital, Wuhan, Hubei, China

🇨🇳

Eye & Ent Hospital of Fudan University, Shanghai, China

🇨🇳

Shanghai First People's Hospital, Shanghai, China

and more 2 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.